 | |
| Clinical data | |
|---|---|
| Other names | SHR3680 |
| Drug class | Nonsteroidal antiandrogen |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C22H20F3N3O4S |
| Molar mass | 479.47 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Rezvilutamide (INNTooltip International Nonproprietary Name),[1][2] sold under the brand nameAriane, is anonsteroidal antiandrogen which is approved for the treatment ofprostate cancer inChina and is or was under development for the treatment ofbreast cancer.[3][4][5] It is aselectiveandrogen receptorantagonist with reducedbraindistribution compared to thestructurally related nonsteroidal antiandrogenenzalutamide.[3][5] The drug was developed byJiangsu Hengrui Medicine.[3] Other structural analogues of rezvilutamide that are also used as antiandrogens besides enzalutamide includeapalutamide andproxalutamide.
 | Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byexpanding it. |
